Ifosfamide chemotherapy of metastatic renal cell cancer

I. Bodrogi, M. Baki, I. Sinkovics, S. Eckhardt

Research output: Contribution to journalArticle

3 Citations (Scopus)


In view of the divergent reports on the efficacy of ifosfamide in metastatic renal cancer, we tested this drug as monotherapy in nine patients on a dosage schedule of intravenous infusion of 40 mg/kg per day on day 1-5, repeated every 4 wk. The drug was administered in 1 liter saline dextrose over 2 hr, with hydration, alkalization of the urine, and mesna. No objective response was registered and subjective response in three patients was of short duration. The number of patients in this series is too small to draw definitive conclusions. However, the results obtained in this study does not prove antitumor activity for ifosfamide in renal cell cancer.

Original languageEnglish
Pages (from-to)95-96
Number of pages2
JournalSeminars in Surgical Oncology
Issue number2
Publication statusPublished - Jan 1 1988

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Ifosfamide chemotherapy of metastatic renal cell cancer'. Together they form a unique fingerprint.

  • Cite this

    Bodrogi, I., Baki, M., Sinkovics, I., & Eckhardt, S. (1988). Ifosfamide chemotherapy of metastatic renal cell cancer. Seminars in Surgical Oncology, 4(2), 95-96.